{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:35:53Z","timestamp":1762497353140,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T00:00:00Z","timestamp":1600560000000},"content-version":"vor","delay-in-days":263,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.4158\/accr-2019-0227","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T14:55:30Z","timestamp":1569509730000},"page":"e30-e32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Unique Case of Atezolizumab-Induced Autoimmune Diabetes"],"prefix":"10.1016","volume":"6","author":[{"given":"Mimi","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirjhar","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashim","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/ACCR-2019-0227_bb0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.4158\/ACCR-2019-0227_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11523-018-0570-5","article-title":"Atezolizumab: a review in previously treated advanced non-small cell lung cancer","volume":"13","author":"Blair","year":"2018","journal-title":"Target Oncol"},{"key":"10.4158\/ACCR-2019-0227_bb0020","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"10.4158\/ACCR-2019-0227_bb0025","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1097\/MJT.0000000000000644","article-title":"Atezolizumab-induced new onset diabetes mellitus with ketoacidosis","volume":"25","author":"Patti","year":"2018","journal-title":"Am J Ther"},{"key":"10.4158\/ACCR-2019-0227_bb0030","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/ACCR-2019-0227_bb0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Spanish Group for Cancer Immuno-Biotherapy","year":"2016","journal-title":"Oncologist"},{"key":"10.4158\/ACCR-2019-0227_bb0040","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.4158\/ACCR-2019-0227_bb0045","first-page":"2017","article-title":"Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies","author":"Way","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.4158\/ACCR-2019-0227_bb0050","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","author":"Kapke","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.4158\/ACCR-2019-0227_bb0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11523-017-0480-y","article-title":"Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature","volume":"12","author":"Hickmott","year":"2017","journal-title":"Target Oncol"},{"key":"10.4158\/ACCR-2019-0227_bb0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1399-5448.2012.00857.x","article-title":"Association between autoantibodies to the arginine variant of the zinc transporter 8 (ZnT8) and stimulated C-peptide levels in Danish children and adolescents with newly diagnosed type 1 diabetes","volume":"13","author":"Andersen","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"10.4158\/ACCR-2019-0227_bb0065","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4103\/0366-6999.163389","article-title":"Current and future clinical applications of zinc transporter-8 in type 1 diabetes mellitus","volume":"128","author":"Yi","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.4158\/ACCR-2019-0227_bb0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41598-017-00307-4","article-title":"Importance of zinc transporter 8 autoantibody in the diagnosis of type 1 diabetes in Latin Americans","volume":"7","author":"Gomes","year":"2017","journal-title":"Sci Rep"},{"key":"10.4158\/ACCR-2019-0227_bb0075","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1507\/endocrj.EJ12-0069","article-title":"ZnT8 and type 1 diabetes","volume":"59","author":"Kawasaki","year":"2012","journal-title":"Endocr J"},{"key":"10.4158\/ACCR-2019-0227_bb0080","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1210\/jc.2003-031887","article-title":"Prediction of autoanti-body positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY)","volume":"89","author":"Barker","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/ACCR-2019-0227_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1753-0407.2010.00102.x","article-title":"Prediction and prevention of type 1 diabetes mellitus","volume":"3","author":"Zhang","year":"2011","journal-title":"J Diabetes"},{"key":"10.4158\/ACCR-2019-0227_bb0090","first-page":"235","article-title":"Immune dysfunction in Australian Aborigines","volume":"23","author":"Roberts-Thomson","year":"2005","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.4158\/ACCR-2019-0227_bb0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","author":"Smati","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.4158\/ACCR-2019-0227_bb0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237606052030064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237606052030064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:31:00Z","timestamp":1762497060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S237606052030064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S237606052030064X"],"URL":"https:\/\/doi.org\/10.4158\/accr-2019-0227","relation":{},"ISSN":["2376-0605"],"issn-type":[{"type":"print","value":"2376-0605"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Unique Case of Atezolizumab-Induced Autoimmune Diabetes","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/ACCR-2019-0227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}